PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1443144-4	1992	Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner.	Pentagastrin	110-122	peptide YY	Canis lupus familiaris	30-33	
1443144-4	1992	Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner.	Pentagastrin	110-122	peptide YY	Canis lupus familiaris	42-45	
1443144-4	1992	Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner.	Pentagastrin	110-122	peptide YY	Canis lupus familiaris	42-45	
2888314-1	1987	The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion.	Pentagastrin	78-90	peptide YY	Canis lupus familiaris	58-68	
2888314-1	1987	The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion.	Pentagastrin	78-90	peptide YY	Canis lupus familiaris	70-73	
2888314-1	1987	The purpose of this study is to investigate the effect of peptide YY (PYY) on pentagastrin-, histamine-, and bethanechol-stimulated gastric acid secretion and the possible mechanisms by which PYY inhibits gastric acid secretion.	Pentagastrin	78-90	peptide YY	Canis lupus familiaris	192-195	
2888314-20	1987	Furthermore, PYY inhibit pentagastrin-stimulated gastric acid secretion in the face of atropine, vagotomy, or indomethacin treatment.	Pentagastrin	25-37	peptide YY	Canis lupus familiaris	13-16	
2156661-7	1990	Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP.	Pentagastrin	56-68	peptide YY	Canis lupus familiaris	152-155	
3671783-4	1987	administration of PYY at 200 pmol/kg/h inhibited pentagastrin (1 microgram/kg/h)-stimulated gastric acid output (P less than 0.05).	Pentagastrin	49-61	peptide YY	Canis lupus familiaris	18-21	
3671783-8	1987	The present study demonstrates that PYY can interact with secretin and duodenal acidification in an additive fashion to inhibit pentagastrin-stimulated gastric acid secretion.	Pentagastrin	128-140	peptide YY	Canis lupus familiaris	36-39	
2868024-3	1986	The present study seeks to determine the mechanism by which PYY inhibits acid secretion by examining the effects of PYY on gastric acid stimulated by pentagastrin, histamine, and bethanechol.	Pentagastrin	150-162	peptide YY	Canis lupus familiaris	60-63	
2868024-3	1986	The present study seeks to determine the mechanism by which PYY inhibits acid secretion by examining the effects of PYY on gastric acid stimulated by pentagastrin, histamine, and bethanechol.	Pentagastrin	150-162	peptide YY	Canis lupus familiaris	116-119	
2868024-6	1986	This same dose of PYY maximally inhibited histamine- and pentagastrin-stimulated acid secretion by 28 +/- 7% (P less than 0.05), and 17 +/- 4% (P less than 0.05), respectively.	Pentagastrin	57-69	peptide YY	Canis lupus familiaris	18-21